描述：加拿大生物技術(shù)公司Microbix Biosystems
---加拿大生物技術(shù)公司Microbix Biosystems（MBX.TO: 行情）周二表示，將與湖南生物醫(yī)藥集團(tuán)聯(lián)手建設(shè)亞洲規(guī)模zui大的流感疫苗生產(chǎn)基地。
Microbix稱(chēng)，已與湖南生物醫(yī)藥集團(tuán)成立合作企業(yè)，共同建設(shè)和運(yùn)營(yíng)位于長(zhǎng)沙市附近兩億美元的疫苗生產(chǎn)基地。
這將是*三大疫苗生產(chǎn)基地。2013年全面投產(chǎn)後，該基地每年將能夠生產(chǎn)超過(guò)1億劑的季節(jié)流感疫苗，以及高達(dá)3億劑的一種可預(yù)防流感大流行病毒的疫苗，包括甲流病毒。預(yù)計(jì)工程將于2010年初啟動(dòng)。
Microbix董事長(zhǎng)兼*執(zhí)行官William Gastle向路透表示：“我們將解決中國(guó)一個(gè)尚未被滿(mǎn)足的醫(yī)療需求，一些國(guó)家疫苗產(chǎn)能不足，無(wú)法滿(mǎn)足國(guó)內(nèi)人口的疫苗需求，中國(guó)就是其中之一。"
| EL-15-02 | 1 ml | |
| EL-01-02 | Cytomegalovirus, Grade 2 | 1 ml |
| EL-22-02 | Dengue Type 2 | 1 ml |
| EL-16-03 | Epstein Barr Virus, Cell Extract | 1 ml |
| EL-16-06 | EBV Viral Capsid Ag, Purified | 1 ml |
| EL-25-01 | Hepatitis A, Grade 2 | 1 ml |
| EL-02-02 | Herpes Simplex 1, Grade 2 | 1 ml |
| EL-23-02 | Herpes Simplex 2, Grade 2 | 1 ml |
| EL-13-02 | Influenza A, Grade 2 | 1 ml |
| EL-13-AD | Influenza A Nucleoprotein *NEW* | 20 ug |
| EL-14-03 | Influenza B, Grade 2 | 1 ml |
| EL-04-02 | Measles, Grade 2 | 1 ml |
| EL-06-02 | Mumps, Grade 2 | 1 ml |
| EL-08-02 | Parainfluenza 1, Grade 2 | 1 ml |
| EL-09-02 | Parainfluenza 2, Grade 2 | 1 ml |
| EL-10-02 | Parainfluenza 3, Grade 2 | 1 ml |
| EL-35-02 | Rotavirus | 1 ml |
| EL-07-02 | Respiratory Syncytial Virus, Grade 2 | 1 ml |
| EL-07-AB | Respiratory Syncytial Virus. Purified *NEW* | 1 mg |
| EL-05-13 | Rubella K0S Concentrate | 1 ml |
| EL-05-10 | Rubella K1S | 1 ml |
| EL-05-11 | Rubella K2S | 1 mg |
| EL-03-02 | Varicella-Zoster, Grade 2 | 1 ml |
| EL-11-02 | Mycoplasma pneumoniae, Grade 2 | 1 ml |
| EL-12-02 | Chlamydia trachomatis, Grade 2 | 1 ml |
| EL-46-02 | Chlamydia pneumoniae | 1 ml |
| PD-01-60 | pΔE1sp1A, pΔE1sp1B, pFG140 and pJM17 | Kit A |
| PD-01-61 | pAB26, pAB27, pFG140 and pFG173 | Kit B |
| PD-01-62 | pΔE1sp1A, pΔE1sp1B, pXC1, pABS.4, pFG140, pBHG10, pBHG11 | Kit C |
| PD-01-64 | pDC311, pDC312, pDC315, pDC316, pBHGloxΔE1,3Cre, pFG140 | |
| PD-01-65 | pDC511, pDC512, pDC515, pDC516, pBHGfrtΔE1,3FLP, and pFG140 | |
| PD-01-67 | pDC411, pDC412, pDC415, pDC416, pBHG10, pBHGE3 and pFG140 | |
| PD-01-66 | AdCreM2, AdfloxLacZ1 and Adfloxluc | |
| PD-01-68 | pDC315（io）, pDC316（io）, pBHGloxΔE1,3Cre, pFG140, 293IQ Cells | |
| PD-01-69 | pDC515（io）, pDC516（io）, pBHGfrtΔE1,3FLP, pFG140, 293IQ Cells | |
| PD-01-01 | pΔE1sp1A | |
| PD-01-02 | pΔE1sp1B | |
| PD-01-03 | pXC1 | |
| PD-01-04 | PABS.4 | |
| PD-01-05 | pFG140 | |
| PD-01-06 | pJM17 | |
| PD-01-07 | pAB26 | |
| PD-01-08 | pAB27 | |
| PD-01-09 | pFG173 | |
| PD-01-10 | PBHG10 | |
| PD-01-11 | PBHG11 | |
| PD-01-12 | PBHGE3 | |
| PD-01-13 | pCA3 | |
| PD-01-14 | pCA4 | |
| PD-01-15 | pCA13 | |
| PD-01-16 | pCA14 | |
| PD-01-17 | pCA17 | |
| PD-01-18 | pCA18 | |
| PD-01-19 | PBHG9 | |
| PD-01-20 | PHCMVsp1LacZ | |
| PD-01-21 | pMH4 | |
| PD-01-22 | pMH5 | |
| PD-01-25 | pDC311 | |
| PD-01-26 | pDC312 | |
| PD-01-27 | pDC315 | |
| PD-01-28 | pDC316 | |
| PD-01-29 | pDC411 | |
| PD-01-30 | pDC412 | |
| PD-01-31 | pDC415 | |
| PD-01-32 | pDC416 | |
| PD-01-33 | pDC511 | |
| PD-01-34 | pDC512 | |
| PD-01-35 | pDC515 | |
| PD-01-36 | pDC516 | |
| PD-01-37 | pBHGfrtΔE1FLP | |
| PD-01-38 | pBHGfrtΔE1,3FLP | |
| PD-01-39 | pBHGloxΔE1Cre | |
| PD-01-40 | pBHGloxΔE1,3Cre | |
| PD-01-41 | pMH5（I） | |
| PD-01-42 | AdCre1 | |
| PD-01-54 | AdCreM2 | |
| PD-01-44 | AdfloxLacZ1 | |
| PD-01-45 | Adfloxluc | |
| PD-01-46 | PDC315（io） | |
| PD-01-47 | PDC316（io） | |
| PD-01-48 | PDC515（io） | |
| PD-01-49 | PDC516（io） | |
| PD-01-53 | Adeno Helper Virus H14 | |
| PD-02-01 | 293 Low Passage Cells | |
| PD-02-02 | 293 N3S Suspension Cells | |
| PD-02-03 | 293 E4pIX Cells | |
| PD-02-04 | 293IQ Cells | |
| PD-02-08 | 293 Cre4 Cells |
